Eye Discharge

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 141 Experts worldwide ranked by ideXlab platform

Paul Little - One of the best experts on this subject based on the ideXlab platform.

  • how do gps diagnose and manage acute infective conjunctivitis a gp survey
    Family Practice, 2002
    Co-Authors: Hazel Everitt, Paul Little
    Abstract:

    Objective: to determine GPs’ diagnosis and management of acute infective conjunctivitis (AIC)—one of the commonest but least researched acute infections seen in primary care. Methods: a postal questionnaire survey of 300 GPs from two Health Authorities in Southern England. Results: 236 (78%) GPs returned the questionnaire. 92% of those responding felt confident or very confident in the diagnosis of AIC. 95% usually prescribe topical antibiotics for AIC despite 58% stating that they thought at least half of the cases they see are viral in origin and only 36% believing that they could discriminate between bacterial and viral infection. There was considerable variability in GPs’ use of individual signs to make the diagnosis of AIC (from 99% using Eye Discharge to 31% using conjunctival oedema) and in the features used to discriminate viral from bacterial infection (from 87% using type of Discharge to 47% using amount of Discharge). GPs rarely perform Eye swabs or give patient information leaflets to patients with AIC. Conclusion: most GPs still prescribe topical antibiotics for most cases of AIC—a condition where only half of the cases are likely to be due to a bacterial infection, and even bacterial infections are self-limiting. Further research is needed to explore the potential benefits and disadvantages of topical antibiotics, and to develop clinical or microbiological methods to help GPs to target antibiotic prescription.

Jacob Cheng Yen Chuan - One of the best experts on this subject based on the ideXlab platform.

  • a randomised parallel group comparison study of diquafosol ophthalmic solution in patients with dry Eye in china and singapore
    British Journal of Ophthalmology, 2015
    Co-Authors: Lan Gong, Luosheng Tang, Wei Han Chua, Yangshun Gu, Huiping Yuan, Yan Shao, Xun Xu, Xiaoming Chen, Qinmei Wang, Jacob Cheng Yen Chuan
    Abstract:

    Aims To compare the efficacy and safety of 3% diquafosol ophthalmic solution with those of 0.1% sodium hyaluronate ophthalmic solution in patients with dry Eye in China and Singapore. Methods A total of 497 patients with dry Eye (Schirmer9s test, 5 mm; fluorescein and RB score, 3 points) from China and Singapore were randomised to receive either diquafosol ophthalmic solution (diquafosol) or sodium hyaluronate ophthalmic solution (HA) at 1:1 ratio. The fluorescein staining scores and rose bengal (RB) subjective symptom scores and tear film breakup time were evaluated before treatment and 2 and 4 weeks after start of treatment. Results In the diquafosol group, changes in fluorescein and RB scores compared with baseline at week 4 or at the time of discontinuation were −2.1±1.5 and −2.5±2.0, respectively. Compared with the HA group, changes in fluorescein score were non-inferior and changes in RB score were superior (p=0.019). In addition, diquafosol and HA improved tear film breakup time by 1.046±1.797 and 0.832±1.775 s, respectively (no significant intergroup difference). Adverse event onset rates were 16.3% (40 of 246 subjects) and 10.0% (25 of 251 subjects) in the diquafosol group and HA group, respectively, with borderline significant intergroup differences (p=0.046), while adverse drug reaction incidence rates were 12.2% (30 of 246 subjects) and 6.0% (15 of 251 subjects), respectively (p=0.019). Only mild adverse drug reactions (>2%) in the form of Eye Discharge, itching or irritation were observed. Conclusions Diquafosol improved fluorescein staining score in a manner similar to HA, and significantly improved RB score compared with HA. Trial registration number NCT01101984.

Hazel Everitt - One of the best experts on this subject based on the ideXlab platform.

  • how do gps diagnose and manage acute infective conjunctivitis a gp survey
    Family Practice, 2002
    Co-Authors: Hazel Everitt, Paul Little
    Abstract:

    Objective: to determine GPs’ diagnosis and management of acute infective conjunctivitis (AIC)—one of the commonest but least researched acute infections seen in primary care. Methods: a postal questionnaire survey of 300 GPs from two Health Authorities in Southern England. Results: 236 (78%) GPs returned the questionnaire. 92% of those responding felt confident or very confident in the diagnosis of AIC. 95% usually prescribe topical antibiotics for AIC despite 58% stating that they thought at least half of the cases they see are viral in origin and only 36% believing that they could discriminate between bacterial and viral infection. There was considerable variability in GPs’ use of individual signs to make the diagnosis of AIC (from 99% using Eye Discharge to 31% using conjunctival oedema) and in the features used to discriminate viral from bacterial infection (from 87% using type of Discharge to 47% using amount of Discharge). GPs rarely perform Eye swabs or give patient information leaflets to patients with AIC. Conclusion: most GPs still prescribe topical antibiotics for most cases of AIC—a condition where only half of the cases are likely to be due to a bacterial infection, and even bacterial infections are self-limiting. Further research is needed to explore the potential benefits and disadvantages of topical antibiotics, and to develop clinical or microbiological methods to help GPs to target antibiotic prescription.

Getachew Ferede - One of the best experts on this subject based on the ideXlab platform.

  • types and drug susceptibility patterns of bacterial isolates from Eye Discharge samples at gondar university hospital northwest ethiopia
    BMC Research Notes, 2014
    Co-Authors: Dagnachew Muluye, Yitayih Wondimeneh, Feleke Moges, Tesfaye Nega, Getachew Ferede
    Abstract:

    The type and pattern of organisms that cause ocular infection changes over time. Moreover, the causative organisms have developed increased drug resistance. Therefore, the aim of this study was to determine the prevalent bacterial agents of Eye Discharge and their drug susceptibility patterns to commonly used antimicrobial agents. A retrospective study was conducted at Gondar University Hospital, Northwest Ethiopia from September, 2009 to August, 2012. Culture and drug susceptibility test results of patients who had Eye infections were taken for analysis. Eye Discharge samples were cultured on MacConkey agar, blood agar and chocolate agar plates. A standard biochemical procedure was used for full identification of bacterial isolates. Antimicrobial susceptibility tests were done on Mueller-Hinton agar by using disk diffusion method. Data was entered and analyzed by using SPSS version 16 software. A total of 102 Eye Discharges were submitted for microbiological evaluation, of which (60.8%) had bacterial growth. The most frequently isolated bacterial isolates were gram-positive bacteria (74.2%). The predominant bacterial species isolated was Coagulase-negative staphylococci (27.4%) followed by S. aureus ( 21%). Within the age group of 1 day-2 years old, (66.1%) of bacteria were isolated. Most of the bacterial isolates were resistance to ampicilin (71%), amoxicilin (62.9%), erythromycin (43.5%), gentamicin (45.2%), penicillin (71%), trimethoprim-sulphamethoxazole (58.1%), and tetracycline (64.6%) while Ceftriaxon and Ciprofloxacin showed (75.8%) and (80%) susceptibility respectively. From the total bacterial isolates, (87.1%) were showed multi drug resistance (MDR) to two or more drugs. The prevalence of bacterial isolates in Eye Discharge was high in the study area and majority of isolates were gram-positive bacteria. Most of the bacterial isolates were resistant to frequently used antimicrobials. Therefore, drug susceptibility test is necessary before prescribing any antimicrobials.

Lan Gong - One of the best experts on this subject based on the ideXlab platform.

  • a randomised parallel group comparison study of diquafosol ophthalmic solution in patients with dry Eye in china and singapore
    British Journal of Ophthalmology, 2015
    Co-Authors: Lan Gong, Luosheng Tang, Wei Han Chua, Yangshun Gu, Huiping Yuan, Yan Shao, Xun Xu, Xiaoming Chen, Qinmei Wang, Jacob Cheng Yen Chuan
    Abstract:

    Aims To compare the efficacy and safety of 3% diquafosol ophthalmic solution with those of 0.1% sodium hyaluronate ophthalmic solution in patients with dry Eye in China and Singapore. Methods A total of 497 patients with dry Eye (Schirmer9s test, 5 mm; fluorescein and RB score, 3 points) from China and Singapore were randomised to receive either diquafosol ophthalmic solution (diquafosol) or sodium hyaluronate ophthalmic solution (HA) at 1:1 ratio. The fluorescein staining scores and rose bengal (RB) subjective symptom scores and tear film breakup time were evaluated before treatment and 2 and 4 weeks after start of treatment. Results In the diquafosol group, changes in fluorescein and RB scores compared with baseline at week 4 or at the time of discontinuation were −2.1±1.5 and −2.5±2.0, respectively. Compared with the HA group, changes in fluorescein score were non-inferior and changes in RB score were superior (p=0.019). In addition, diquafosol and HA improved tear film breakup time by 1.046±1.797 and 0.832±1.775 s, respectively (no significant intergroup difference). Adverse event onset rates were 16.3% (40 of 246 subjects) and 10.0% (25 of 251 subjects) in the diquafosol group and HA group, respectively, with borderline significant intergroup differences (p=0.046), while adverse drug reaction incidence rates were 12.2% (30 of 246 subjects) and 6.0% (15 of 251 subjects), respectively (p=0.019). Only mild adverse drug reactions (>2%) in the form of Eye Discharge, itching or irritation were observed. Conclusions Diquafosol improved fluorescein staining score in a manner similar to HA, and significantly improved RB score compared with HA. Trial registration number NCT01101984.